Partnership aims to accelerate development using computational drug design

Creyon Bio has entered into a licensing and multi-target research collaboration with Eli Lilly focused on developing RNA-targeted oligonucleotide (oligo) therapies for a range of diseases. The companies will combine Creyon’s computational drug design platform with Lilly’s development and commercialization capabilities.

Creyon says its AI-powered Oligo Engineering Engine applies quantum chemistry principles to optimize oligo design, offering an alternative to traditional trial-and-error screening methods. The company believes this approach could improve both speed and precision in the development of nucleic acid therapeutics.

Under the terms of the agreement, Creyon will receive $13 million upfront, including cash and equity investment. The company may also receive more than $1 billion in development and commercial milestone payments, depending on progress across multiple targets. Lilly gains an exclusive license to lead candidates and will take over research and development following achievement of defined milestones.

The collaboration is expected to target both rare and common diseases, though specific indications have not been disclosed.

Creyon, based in San Diego, is developing oligo-based therapeutics that combine computational modelling with tissue-specific delivery techniques. According to the company, its platform is designed to streamline the discovery of safe and effective RNA-targeted therapies.